A maze with an image of a brain at the center and images of a 96 well plate and a DNA helix at the periphery

The Clinical Pipeline

Growing interest in non-invasive brain–computer interfaces, rather than implants, might improve accessibility for patients, but resolution needs to be improved.


  • People of different ages and backgrounds coming together to form a healthy population

    Women’s health has been underfunded and underprioritized for too long, leading to delays in diagnosis and poor health outcomes. This series will bring together a range of viewpoints and new research focusing on the causes of ill health in women and the barriers to their health and wellbeing in the 21st Century.

  • evidence in medicine

    New therapeutics and health technologies require fresh approaches to demonstrating safety and efficacy. This collection brings together key stakeholders to discuss how evidence-based medicine should evolve to assess these technological advances, from gene editing to artificial intelligence health algorithms.

  • dei series

    This ongoing series brings together a range of viewpoints on DEI in medical research, covering topics such as funding biases, workforce diversity and how to fix the lack of diversity of health data. Reach out to us to contribute your perspective.

Nature Medicine is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.


  • Next-generation liquid biopsy technologies that target the detection of cell-free DNA with fragments of circulating tumor DNA could be a game-changer in early cancer detection, but their adoption requires further clinical testing and consideration of harm.

  • An early-phase trial suggests safety and improvements in vision after treatment with the CRISPR-based therapy EDIT-101, providing proof of concept for in vivo retinal gene editing.

    • Karen O’Leary
    Research Highlight
  • Final results of two studies — whose preliminary data led to regulatory approval of the gene therapy exagamglogene autotemcel — describe highly effective treatment of sickle-cell disease and transfusion-dependent β-thalassemia.

    • Karen O’Leary
    Research Highlight

Nature Careers

Science jobs